Parkinson’s disease and enhanced inflammatory response

Experimental Biology and Medicine

Volumn 240, Issue 11, 2015, Pages 1387-1395

  Stojkovska, Iva ^a   Wagner, Brandon M ^a   Morrison, Brad E ^a  

^a BOISE STATE UNIVERSITY   (United States)

Author keywords

disease models; inflammation; neuroinflammation; Parkinson s disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CYTOKINE; DJ 1 PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEUCINE RICH REPEAT KINASE 2; LIPOPOLYSACCHARIDE; NEUROTOXIN; OXIDOPAMINE; PARAQUAT; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SILYMARIN; DOPAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; UBIQUITIN PROTEIN LIGASE;

BEHAVIOR; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; ANIMAL; CHEMISTRY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; IMMUNOLOGY; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; NEURONS; OXIDATIVE STRESS; OXIDOPAMINE; OXYGEN; PARAQUAT; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES;

EID: 84940442583     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370215576313     Document Type: Review

References (115)

1. L.M.de LauM.M.Breteler. Epidemiology of Parkinson’s disease. Lancet Neurol2006; 5: 525–35.
2. J.JankovicM.Stacy. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs2007; 21: 677–92.
3. M.KastenA.ChadeC.M.Tanner. Epidemiology of Parkinson’s disease. Handb Clin Neurol2007; 83: 129–51.
4. P.L.McGeerS.ItagakiB.E.BoyesE.G.McGeer. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology1988; 38: 1285–91.
5. J.M.TaylorB.S.MainP.J.Crack. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson’s disease. Neurochem Int2013; 62: 803–19.
6. D.C.DukeL.B.MoranR.K.PearceM.B.Graeber. The medial and lateral substantia nigra in Parkinson’s disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics2007; 8: 83–94.
7. H.ChenS.M.ZhangM.A.HernánM.A.SchwarzschildW.C.WillettG.A.ColditzF.E.SpeizerA.Ascherio. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol2003; 60: 1059–64.
8. K.ReesR.StoweS.PatelN.IvesK.BreenC.E.ClarkeY.Ben-Shlomo. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies. Cochrane Database Syst Rev2011, pp. CD008454–CD008454.
9. A.D.WahnerJ.M.BronsteinY.M.BordelonB.Ritz. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology2007; 69: 1836–42.
10. X.GaoH.ChenM.A.SchwarzschildA.Ascherio. Use of ibuprofen and risk of Parkinson disease. Neurology2011; 76: 863–9.
11. D.B.HancockE.R.MartinJ.M.StajichR.JewettM.A.StacyB.L.ScottJ.M.VanceW.K.Scott. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol2007; 64: 576–80.
12. M.A.HernánG.LogroscinoL.A.García Rodríguez. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology2006; 66: 1097–9.
13. S.M.GoldmanC.M.TannerD.OakesG.S.BhudhikanokA.GuptaJ.W.Langston. Head injury and Parkinson’s disease risk in twins. Ann Neurol2006; 60: 65–72.
14. J.H.BowerD.M.MaraganoreB.J.PetersonJ.E.AhlskogW.A.Rocca. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology2006; 67: 494–6.
15. N.A.LeopoldW.Bara-JimenezM.Hallett. Parkinsonism after a wasp sting. Mov Disord1999; 14: 122–7.
16. P.MinaultM.MadigandO.Sabouraud. Pallidostriatal necrosis after Hymenoptera sting. Parkinsonian syndrome. La Nouvelle presse medicale1981; 10: 3725–6.
17. T.C.Frank-CannonT.TranK.A.RuhnT.N.MartinezJ.HongM.MarvinM.HartleyI.TreviñoD.E.O'BrienB.CaseyM.S.GoldbergM.G.Tansey. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci2008; 28: 10825–34.
18. Q.HeW.YuJ.WuC.ChenZ.LouQ.ZhangJ.ZhaoJ.WangB.Xiao. Intranasal LPS-mediated Parkinson’s model challenges the pathogenesis of nasal cavity and environmental toxins. PLoS One2013; 8: e78418–e78418.
19. L.QinX.WuM.L.BlockY.LiuG.R.BreeseJ.S.HongD.J.KnappF.T.Crews. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia2007; 55: 453–62.
20. C.P.RamseyM.G.Tansey. A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson’s disease and potential molecular targets. Exp Neurol2014; 256: 126–32.
21. H.M.GaoP.T.KotzbauerK.UryuS.LeightJ.Q.TrojanowskiV.M.Lee. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci2008; 28: 7687–98.
22. M.G.TanseyM.K.McCoyT.C.Frank-Cannon. Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol2007; 208: 1–25.
23. V.BrochardB.CombadièreA.PrigentY.LaouarA.PerrinV.Beray-BerthatO.BonduelleD.Alvarez-FischerJ.CallebertJ.M.LaunayC.DuyckaertsR.A.FlavellE.C.HirschS.Hunot. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest2009; 119: 182–92.
24. M.L.BlockJ.S.Hong. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans2007; 35: 1127–32.
25. I.MiyazakiM.Asanuma. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama2008; 62: 141–50.
26. S.GiordanoV.Darley-UsmarJ.Zhang. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol2014; 2: 82–90.
27. G.RameshA.G.MacLeanM.T.Philipp. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm2013; 2013: 480739–480739.
28. M.G.TanseyM.S.Goldberg. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis2010; 37: 510–8.
29. A.PoltorakX.HeI.SmirnovaM.Y.LiuC.Van HuffelX.DuD.BirdwellE.AlejosM.SilvaC.GalanosM.FreudenbergP.Ricciardi-CastagnoliB.LaytonB.Beutler. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science1998; 282: 2085–8.
30. Y.C.LuW.C.YehP.S.Ohashi. LPS/TLR4 signal transduction pathway. Cytokine2008; 42: 145–51.
31. A.CastañoA.J.HerreraJ.CanoA.Machado. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem1998; 70: 1584–92.
32. A.J.HerreraA.CastañoJ.L.VeneroJ.CanoA.Machado. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis2000; 7: 429–47.
33. X.LuG.BingT.Hagg. Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience2000; 97: 285–91.
34. M.C.Hernández-RomeroS.ArgüellesR.F.VillaránR.M.de PablosM.J.Delgado-CortésM.SantiagoA.J.HerreraJ.CanoA.Machado. Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J Neurochem2008; 105: 445–59.
35. M.M.IravaniM.SadeghianC.C.LeungP.JennerS.Rose. Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor. Neurosci Lett2012; 510: 138–42.
36. L.H.BradleyJ.FuquaA.RichardsonJ.Turchan-CholewoY.AiK.A.KelpsJ.D.GlassX.HeZ.ZhangR.GrondinO.M.LittrellP.HuettlF.PomerleauD.M.GashG.A.Gerhardt. Dopamine neuron stimulating actions of a GDNF propeptide. PLoS One2010; 5: e9752–e9752.
37. S.S.ChenC.YangF.HaoC.LiT.LuL.R.ZhaoW.M.Duan. Intrastriatal GDNF gene transfer by inducible lentivirus vectors protects dopaminergic neurons in a rat model of parkinsonism. Exp Neurol2014; 261C: 87–96.
38. D.Y.ChoiM.LiuR.L.HunterW.A.CassJ.D.PandyaP.G.SullivanE.J.ShinH.C.KimD.M.GashG.Bing. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One2009; 4: e5482–e5482.
39. R.L.HunterB.ChengD.Y.ChoiM.LiuS.LiuW.A.CassG.Bing. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res2009; 87: 1913–21.
40. R.L.HunterN.DragicevicK.SeifertD.Y.ChoiM.LiuH.C.KimW.A.CassP.G.SullivanG.Bing. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem2007; 100: 1375–86.
41. Y.ZhouY.ZhangJ.LiF.LvY.ZhaoD.DuanQ.Xu. A comprehensive study on long-term injury to nigral dopaminergic neurons following intracerebroventricular injection of lipopolysaccharide in rats. J Neurochem2012; 123: 771–80.
42. U.BickelB.GraveY.S.KangA.del ReyK.Voigt. No increase in blood-brain barrier permeability after intraperitoneal injection of endotoxin in the rat. J Neuroimmunol1998; 85: 131–6.
43. W.PanA.J.Kastin. TNF-α transport across the blood-brain barrier is abolished in receptor knockout mice. Exp Neurol2002; 174: 193–200.
44. W.A.Banks. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des2005; 11: 973–84.
45. B.E.MorrisonM.C.MarcondesD.K.NomuraM.Sanchez-AlavezA.Sanchez-GonzalezI.SaarK.S.KimT.BartfaiP.MaherS.SugamaB.Conti. Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J Immunol2012; 189: 5498–502.
46. H.BraakK.Del TrediciU.RübR.A.de VosE.N.Jansen SteurE.Braak. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging2003; 24: 197–211.
47. P.ChakrabartyC.Ceballos-DiazW.L.LinA.BeccardK.Jansen-WestN.R.McFarlandC.JanusD.DicksonP.DasT.E.Golde. Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification. Nat Neurosci2011; 14: 694–6.
48. J.W.LangstonP.BallardJ.W.TetrudI.Irwin. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science1983; 219: 979–80.
49. S.PrzedborskiV.Jackson-Lewis. Mechanisms of MPTP toxicity. Mov Disord1998; 13: 35–8.
50. N.J.RiachiJ.C.LaMannaS.I.Harik. Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain. J Pharmacol Exp Ther1989; 249: 744–8.
51. E.MariesB.DassT.J.CollierJ.H.KordowerK.Steece-Collier. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci2003; 4: 727–38.
52. J.N.JohannessenC.C.ChiuehR.S.BurnsS.P.Markey. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci1985; 36: 219–24.
53. R.J.SmeyneV.Jackson-Lewis. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res2005; 134: 57–66.
54. A.CzłonkowskaM.KohutnickaI.Kurkowska-JastrzebskaA.Członkowski. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson’s disease mice model. Neurodegeneration1996; 5: 137–43.
55. M.P.MountA.LiraD.GrimesP.D.SmithS.FaucherR.SlackH.AnismanS.HayleyD.S.Park. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci2007; 27: 3328–37.
56. K.SriramJ.M.MathesonS.A.BenkovicD.B.MillerM.I.LusterJ.P.O’Callaghan. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease. FASEB J2002; 16: 1474–6.
57. C.BarciaC.M.RosV.AnneseA.GómezF.Ros-BernalD.Aguado-YeraM.E.Martínez-PagánV.de PablosE.Fernandez-VillalbaM.T.Herrero. IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson’s disease. Cell Death Dis2011; 2: e142–e142.
58. D.K.NomuraB.E.MorrisonJ.L.BlankmanJ.Z.LongS.G.KinseyM.C.MarcondesA.M.WardY.K.HahnA.H.LichtmanB.ContiB.F.Cravatt. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science2011; 334: 809–13.
59. F.GiulianiW.HaderV.W.Yong. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol2005; 78: 135–43.
60. Y.DuZ.MaS.LinR.C.DodelF.GaoK.R.BalesL.C.TriarhouE.ChernetK.W.PerryD.L.NelsonS.LueckeL.A.PhebusF.P.BymasterS.M.Paul. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci USA2001; 98: 14669–74.
61. M.SwiątkiewiczM.ZarembaI.JoniecA.CzłonkowskiI.Kurkowska-Jastrzębska. Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson’s disease. Pharmacol Rep2013; 65: 1227–36.
62. M.M.KhanD.KempurajR.ThangavelA.Zaheer. Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol. Neurochem Int2013; 62: 379–88.
63. M.GeedD.GarabaduA.AhmadS.Krishnamurthy. Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats. Pharmacol Biochem Behav2014; 117: 92–103.
64. S.J.TsaiW.W.KuoW.H.LiuM.C.Yin. Antioxidative and anti-inflammatory protection from carnosine in the striatum of MPTP-treated mice. J Agric Food Chem2010; 58: 11510–6.
65. C.BerryC.La VecchiaP.Nicotera. Paraquat and Parkinson’s disease. Cell Death Differ2010; 17: 1115–25.
66. M.G.PurisaiA.L.McCormackS.CumineJ.LiM.Z.IslaD.A.Di Monte. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis2007; 25: 392–400.
67. G.SrivastavaA.DixitS.YadavD.K.PatelO.PrakashM.P.Singh. Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb- and paraquat-induced parkinsonism in the mouse. Free Radic Biol Med2012; 52: 1294–306.
68. G.CohenR.E.Heikkila. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem1974; 249: 2447–52.
69. M.SadeghianL.Marinova-MutafchievaL.BroomJ.B.DavisD.VirleyA.D.MedhurstD.T.Dexter. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. J Neuroimmunol2012; 246: 69–77.
70. Y.HeS.AppelW.Le. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res2001; 909: 187–93.
71. R.Sánchez-PernauteA.FerreeO.CooperM.YuA.L.BrownellO.Isacson. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson’s disease. J Neuroinflammation2004; 1: 6–6.
72. M.MogiA.TogariK.TanakaN.OgawaH.IchinoseT.Nagatsu. Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci Lett2000; 289: 165–8.
73. M.K.McCoyT.N.MartinezK.A.RuhnD.E.SzymkowskiC.G.SmithB.R.BottermanK.E.TanseyM.G.Tansey. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci2006; 26: 9365–75.
74. P.ShrivastavaK.VaibhavR.TabassumA.KhanT.IshratM.M.KhanA.AhmadF.IslamM.M.Safhi. Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model. J Nutr Biochem2013; 24: 680–7.
75. A.KumarN.SharmaA.GuptaH.KaloniaJ.Mishra. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. Brain Res2012; 1471: 13–22.
76. Y.C.LeeC.H.LinR.M.WuM.S.LinJ.W.LinC.H.ChangM.S.Lai. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology2013; 81: 410–6.
77. B.FriedmanA.LahadY.DresnerS.Vinker. Long-term statin use and the risk of Parkinson’s disease. Am J Managed Care2013; 19: 626–32.
78. K.SekiyamaS.SugamaM.FujitaA.SekigawaY.TakamatsuM.WaragaiT.TakenouchiM.Hashimoto. Neuroinflammation in Parkinson’s disease and related disorders: a lesson from genetically manipulated mouse models of α-synucleinopathies. Parkinsons Dis2012; 2012: 271732–271732.
79. M.M.WilhelmusP.G.NijlandB.DrukarchH.E.de VriesJ.van Horssen. Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. Free Radic Biol Med2012; 53: 983–92.
80. M.H.PolymeropoulosJ.J.HigginsL.I.GolbeW.G.JohnsonS.E.IdeG.Di IorioG.SangesE.S.StenroosL.T.PhoA.A.SchafferA.M.LazzariniR.L.NussbaumR.C.Duvoisin. Mapping of a gene for Parkinson’s disease to chromosome 4q21–q23. Science1996; 274: 1197–9.
81. S.ChandraX.ChenJ.RizoR.JahnT.C.Sudhof. A broken alpha-helix in folded alpha-Synuclein. J Biol Chem2003; 278: 15313–8.
82. K.A.ConwayS.J.LeeJ.C.RochetT.T.DingJ.D.HarperR.E.WilliamsonP.T.Lansbury. Accelerated oligomerization by Parkinson’s disease linked alpha-synuclein mutants. Ann NY Acad Sci2000; 920: 42–5.
83. P.IbáñezA.M.BonnetB.DébargesE.LohmannF.TisonP.PollakY.AgidA.DürrA.Brice. Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet2004; 364: 1169–71.
84. H.J.Kim. Alpha-synuclein expression in patients with Parkinson’s disease: a clinician’s perspective. Exp Neurobiol2013; 22: 77–83.
85. Y.CouchL.Alvarez-ErvitiN.R.SibsonM.J.WoodD.C.Anthony. The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation2011; 8: 166–166.
86. H.M.GaoF.ZhangH.ZhouW.KamB.WilsonJ.S.Hong. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect2011; 119: 807–14.
87. L.J.MartinY.PanA.C.PriceW.SterlingN.G.CopelandN.A.JenkinsD.L.PriceM.K.Lee. Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci2006; 26: 41–50.
88. H.F.PoonM.FrasierN.ShreveV.CalabreseB.WolozinD.A.Butterfield. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice—a model of familial Parkinson’s disease. Neurobiol Dis2005; 18: 492–8.
89. M.LeeD.HyunB.HalliwellP.Jenner. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem2001; 76: 998–1009.
90. M.B.WatsonF.RichterS.K.LeeL.GabbyJ.WuE.MasliahR.B.EffrosM.F.Chesselet. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol2012; 237: 318–34.
91. K.K.PapachroniN.NinkinaA.PapapanagiotouG.M.HadjigeorgiouG.XiromerisiouA.PapadimitriouA.KalofoutisV.L.Buchman. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem2007; 101: 749–56.
92. E.MasliahE.RockensteinA.AdameM.AlfordL.CrewsM.HashimotoP.SeubertM.LeeJ.GoldsteinT.ChilcoteD.GamesD.Schenk. Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron2005; 46: 857–68.
93. P.DesplatsH.J.LeeE.J.BaeC.PatrickE.RockensteinL.CrewsB.SpencerE.MasliahS.J.Lee. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA2009; 106: 13010–5.
94. C.Paisán-RuízS.JainE.W.EvansW.P.GilksJ.SimónM.van der BrugA.López de MunainS.AparicioA.M.GilN.KhanJ.JohnsonJ.R.MartinezD.NichollI.M.CarreraA.S.PenaR.de SilvaA.LeesJ.F.Martí-MassóJ.Pérez-TurN.W.WoodA.B.Singleton. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron2004; 44: 595–600.
95. A.ZimprichS.BiskupP.LeitnerP.LichtnerM.FarrerS.LincolnJ.KachergusM.HulihanR.J.UittiD.B.CalneA.J.StoesslR.F.PfeifferN.PatengeI.C.CarbajalP.ViereggeF.AsmusB.Müller-MyhsokD.W.DicksonT.MeitingerT.M.StromZ.K.WszolekT.Gasser. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron2004; 44: 601–7.
96. S.GoldwurmA.Di FonzoE.J.SimonsC.F.RohéM.ZiniM.CanesiS.TeseiA.ZecchinelliA.AntoniniC.MarianiN.MeucciG.SacilottoF.SironiG.SalaniJ.FerreiraH.F.ChienE.FabrizioN.VanacoreA.Dalla LiberaF.StocchiC.DiromaP.LambertiC.SampaioG.MecoE.BarbosaA.M.Bertoli-AvellaG.J.BreedveldB.A.OostraG.PezzoliV.Bonifati. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet2005; 42: e65–e65.
97. W.W.SmithZ.PeiH.JiangD.J.MooreY.LiangA.B.WestV.L.DawsonT.M.DawsonC.A.Ross. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA2005; 102: 18676–81.
98. I.RussoL.BubaccoE.Greggio. LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?J Neuroinflammation2014; 11: 52–52.
99. F.R.ZhangW.HuangS.M.ChenL.D.SunH.LiuY.LiY.CuiX.X.YanH.T.YangR.D.YangT.S.ChuC.ZhangL.ZhangJ.W.HanG.Q.YuC.QuanY.X.YuZ.ZhangB.Q.ShiL.H.ZhangH.ChengC.Y.WangY.LinH.F.ZhengX.A.FuX.B.ZuoQ.WangH.LongY.P.SunY.L.ChengH.Q.TianF.S.ZhouH.X.LiuW.S.LuS.M.HeW.L.DuM.ShenQ.Y.JinY.WangH.Q.LowT.ErwinN.H.YangJ.Y.LiX.ZhaoY.L.JiaoL.G.MaoG.YinZ.X.JiangX.D.WangJ.P.YuZ.H.HuC.H.GongY.Q.LiuR.Y.LiuD.M.WangD.WeiJ.X.LiuW.K.CaoH.Z.CaoY.P.LiW.G.YanS.Y.WeiK.J.WangM.L.HibberdS.YangX.J.ZhangJ.J.Liu. Genomewide association study of leprosy. N Engl J Med2009; 361: 2609–18.
100. A.FrankeD.P.McGovernJ.C.BarrettK.WangG.L.Radford-SmithT.AhmadC.W.LeesT.BalschunJ.LeeR.RobertsC.A.AndersonJ.C.BisS.BumpsteadD.EllinghausE.M.FestenM.GeorgesT.GreenT.HarituniansL.JostinsA.LatianoC.G.MathewG.W.MontgomeryN.J.PrescottS.RaychaudhuriJ.I.RotterP.SchummY.SharmaL.A.SimmsK.D.TaylorD.WhitemanC.WijmengaR.N.BaldassanoM.BarclayT.M.BaylessS.BrandC.BüningA.CohenJ.F.ColombelM.CottoneL.StronatiT.DensonM.De VosR.D'IncaM.DubinskyC.EdwardsT.FlorinD.FranchimontR.GearryJ.GlasA.Van GossumS.L.GutheryJ.HalfvarsonH.W.VerspagetJ.P.HugotA.KarbanD.LaukensI.LawranceM.LemannA.LevineC.LibioulleE.LouisC.MowatW.NewmanJ.PanésA.PhillipsD.D.ProctorM.RegueiroR.RussellP.RutgeertsJ.SandersonM.SansF.SeiboldA.H.SteinhartP.C.StokkersL.TorkvistG.Kullak-UblickD.WilsonT.WaltersS.R.TarganS.R.BrantJ.D.RiouxM.D'AmatoR.K.WeersmaS.KugathasanA.M.GriffithsJ.C.MansfieldS.VermeireR.H.DuerrM.S.SilverbergJ.SatsangiS.SchreiberJ.H.ChoV.AnneseH.HakonarsonM.J.DalyM.Parkes. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet2010; 42: 1118–25.
101. A.GardetY.BenitaC.LiB.E.SandsI.BallesterC.StevensJ.R.KorzenikJ.D.RiouxM.J.DalyR.J.XavierD.K.Podolsky. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol2010; 185: 5577–85.
102. F.GillardonR.SchmidH.Draheim. Parkinson’s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience2012; 208: 41–8.
103. J.ParkS.B.LeeS.LeeY.KimS.SongS.KimE.BaeJ.KimM.ShongJ.M.KimJ.Chung. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature2006; 441: 1157–61.
104. J.C.GreeneA.J.WhitworthI.KuoL.A.AndrewsM.B.FeanyL.J.Pallanck. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA2003; 100: 4078–83.
105. K.K.ChungB.ThomasX.LiO.PletnikovaJ.C.TroncosoL.MarshV.L.DawsonT.M.Dawson. S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science2004; 304: 1328–31.
106. Y.KurodaT.MitsuiM.KunishigeT.Matsumoto. Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem Biophys Res Commun2006; 348: 787–93.
107. T.A.TranA.D.NguyenJ.ChangM.S.GoldbergJ.K.LeeM.G.Tansey. Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS One2011; 6: e23660–e23660.
108. S.ShendelmanA.JonasonC.MartinatT.LeeteA.Abeliovich. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol2004; 2: e362–e362.
109. R.BandopadhyayA.E.KingsburyM.R.CooksonA.R.ReidI.M.EvansA.D.HopeA.M.PittmanT.LashleyR.Canet-AvilesD.W.MillerC.McLendonC.StrandA.J.LeonardP.M.Abou-SleimanD.G.HealyH.ArigaN.W.WoodR.de SilvaT.ReveszJ.A.HardyA.J.Lees. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain2004; 127: 420–30.
110. P.J.KahleJ.WaakT.Gasser. DJ-1 and prevention of oxidative stress in Parkinson’s disease and other age-related disorders. Free Radic Biol Med2009; 47: 1354–61.
111. J.WaakS.S.WeberA.WaldenmaierK.GörnerM.Alunni-FabbroniH.SchellD.Vogt-WeisenhornT.T.PhamV.ReumersV.BaekelandtW.WurstP.J.Kahle. Regulation of astrocyte inflammatory responses by the Parkinson’s disease-associated gene DJ-1. FASEB J2009; 23: 2478–89.
112. A.B.Manning-BoğW.M.CaudleX.A.PerezS.H.ReaneyR.PaletzkiM.Z.IslaV.P.ChouA.L.McCormackG.W.MillerJ.W.LangstonC.R.GerfenD.A.Dimonte. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis2007; 27: 141–50.
113. T.A.NguyenT.Frank-CannonT.N.MartinezK.A.RuhnM.MarvinB.CaseyI.TreviñoJ.J.HongM.S.GoldbergM.G.Tansey. Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J Neuroinflammation2013; 10: 50–50.
114. M.E.HaqueM.P.MountF.SafarpourE.Abdel-MessihS.CallaghanC.MazerolleT.KitadaR.S.SlackV.WallaceJ.ShenH.AnismanD.S.Park. Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1. J Biol Chem2012; 287: 23162–70.
115. R.S.AkundiZ.HuangJ.EasonJ.D.PandyaL.ZhiW.A.CassP.G.SullivanH.Büeler. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS One2011; 6: e16038–e16038.